Metformin extends *C. elegans* lifespan through lysosomal pathway

Jie Chen¹,2†, Yuhui Ou¹†, Yi Li¹,2, Shumei Hu¹,2, Li-Wa Shao¹,2, Ying Liu¹*

¹State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China; ²Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

**Abstract** Metformin, a widely used first-line drug for treatment of type 2 diabetes (T2D), has been shown to extend lifespan and delay the onset of age-related diseases. However, its primary locus of action remains unclear. Using a pure in vitro reconstitution system, we demonstrate that metformin acts through the v-ATPase-Ragulator lysosomal pathway to coordinate mTORC1 and AMPK, two hubs governing metabolic programs. We further show in *Caenorhabditis elegans* that both v-ATPase-mediated TORC1 inhibition and v-ATPase-AXIN/LKB1-mediated AMPK activation contribute to the lifespan extension effect of metformin. Elucidating the molecular mechanism of metformin regulated healthspan extension will boost its therapeutic application in the treatment of human aging and age-related diseases.

**Introduction**

With the discovery that aging could be genetically regulated, numerous strategies have been employed to extend lifespan in model organisms, including pharmacologic and dietary interventions (Longo et al., 2015). Identification of a chemical or pharmacological manipulation that could target human aging and lower the risks associated with age-related diseases becomes a central goal of aging research. Administration of metformin, a first-line drug for treatment of type 2 diabetes (T2D), has been shown to extend lifespan in *C. elegans* and mice (Anisimov et al., 2008; Cabreiro et al., 2013; De Haes et al., 2014; Martin-Montalvo et al., 2013; Onken and Driscoll, 2010; Wu et al., 2016). In addition, metformin has been shown to ameliorate diabetic and cardiovascular diseases in patients (Scarpello, 2003). Metformin also lowered the incidence of several other age-related diseases, such as cancer, metabolic syndrome and cognitive disorders (Foretz et al., 2014). Due to its broad range of health benefits and little side effects, a clinical trial named TAME (Targeting Aging with Metformin) was proposed to evaluate metformin’s protective effects against human aging and age-related diseases (Barzilai et al., 2016). However, despite its intriguing benefits to promote healthy aging, the underlying mode of action of metformin is not well understood and a subject of extensive debate.

Metformin is generally believed to act through activation of AMP-activated protein kinase (AMPK) (Fryer et al., 2002; Hawley et al., 2002; Zhou et al., 2001), a principal energy sensor that when activated, switches on catabolic pathways such as glycolysis and fatty acid oxidation to produce more ATP (Burkewitz et al., 2014; Hardie et al., 2012). It was proposed that metformin might act through inhibition of mitochondrial electron transport chain (ETC) Complex I (El-Mir et al., 2000; Foretz et al., 2014; Owen et al., 2000), resulting in a change of the AMP/ATP ratio and ultimately activating AMPK. However, this idea has been challenged recently (He and Wondisford, 2015), especially when physiological/low concentration (~70 uM) of metformin, which cannot induce AMP/ATP change, is still able to activate AMPK (Cao et al., 2014). An alternative model, in which metformin activates AMPK through the lysosome-dependent pathway was proposed (Zhang et al., 2016).
In this model, metformin treatment induces lysosomal localization of the scaffold protein AXIN, which brings its associated protein liver kinase B1 (LKB1) to form a complex with v-ATPase-Ragulator on the surface of lysosome (Zhang et al., 2016; Zhang et al., 2013). LKB1 then phosphorylates the threonine residue in the activation loop of AMPK, leading to AMPK activation (Hawley et al., 1996; Shaw et al., 2004; Woods et al., 2003).

In addition to AMPK activation, metformin administration also inhibits mechanistic target of rapamycin complex 1 (mTORC1) (Kalender et al., 2010). mTORC1 constitutes another hub for energy and nutrient sensing, and switches on anabolism when activated (Schmelzle and Hall, 2000). The primary pathway for mTORC1 activation requires lysosome-localized Rag GTPases, which form RagA/B–RagC/D heterodimers and recruit mTORC1 to the surface of lysosome through directly binding to the Raptor subunit of mTORC1 (Kim et al., 2008; Sancak et al., 2008). v-ATPase-Ragulator complex on lysosomal surface is required for the spatial regulation and activation of mTORC1 by Rag GTPases (Bar-Peled et al., 2012; Dibble and Manning, 2013; Jewell et al., 2013; Sancak et al., 2010). Two distinct mechanisms have been proposed for metformin-induced mTORC1 inhibition: suppression of Rag GTPases (AMPK-independent mechanism) or AMPK-mediated phosphorylation of Raptor (regulatory associated protein of mTORC1) (AMPK-dependent mechanism) (Howell et al., 2017; Kalender et al., 2010).

Due to its short lifespan and ease of genetic manipulation, C. elegans becomes a powerful model organism to test the efficacy of metformin in promoting healthspan (Burkewitz et al., 2014). It has been shown that metformin treatment greatly extends worm lifespan and improves fitness, for example prolonging locomotory ability (Onken and Driscoll, 2010). However, several different mechanisms have been suggested for metformin’s lifespan extension effect in C. elegans. For instance, metformin administration may mimic a dietary restriction (DR) metabolism (Onken and Driscoll, 2010). In addition, alteration of methionine metabolism in C. elegans has been shown to play a partial role (Cabreiro et al., 2013). Recently, metformin has been shown to inhibit mTORC1 due to restricted transit of RagA-RagC GTPase through nuclear pore complex (NPC) (Wu et al., 2016). It is possible that these observations reflect downstream consequences of a primary action of metformin. Therefore, understanding its direct mechanism of action worth further investigation.

DOI: https://doi.org/10.7554/eLife.31268.002

Chen et al. eLife 2017;6:e31268. DOI: https://doi.org/10.7554/eLife.31268

In this model, metformin treatment induces lysosomal localization of the scaffold protein AXIN, which brings its associated protein liver kinase B1 (LKB1) to form a complex with v-ATPase-Ragulator on the surface of lysosome (Zhang et al., 2016; Zhang et al., 2013). LKB1 then phosphorylates the threonine residue in the activation loop of AMPK, leading to AMPK activation (Hawley et al., 1996; Shaw et al., 2004; Woods et al., 2003).

In addition to AMPK activation, metformin administration also inhibits mechanistic target of rapamycin complex 1 (mTORC1) (Kalender et al., 2010). mTORC1 constitutes another hub for energy and nutrient sensing, and switches on anabolism when activated (Schmelzle and Hall, 2000). The primary pathway for mTORC1 activation requires lysosome-localized Rag GTPases, which form RagA/B–RagC/D heterodimers and recruit mTORC1 to the surface of lysosome through directly binding to the Raptor subunit of mTORC1 (Kim et al., 2008; Sancak et al., 2008). v-ATPase-Ragulator complex on lysosomal surface is required for the spatial regulation and activation of mTORC1 by Rag GTPases (Bar-Peled et al., 2012; Dibble and Manning, 2013; Jewell et al., 2013; Sancak et al., 2010). Two distinct mechanisms have been proposed for metformin-induced mTORC1 inhibition: suppression of Rag GTPases (AMPK-independent mechanism) or AMPK-mediated phosphorylation of Raptor (regulatory associated protein of mTORC1) (AMPK-dependent mechanism) (Howell et al., 2017; Kalender et al., 2010).

Due to its short lifespan and ease of genetic manipulation, C. elegans becomes a powerful model organism to test the efficacy of metformin in promoting healthspan (Burkewitz et al., 2014). It has been shown that metformin treatment greatly extends worm lifespan and improves fitness, for example prolonging locomotory ability (Onken and Driscoll, 2010). However, several different mechanisms have been suggested for metformin’s lifespan extension effect in C. elegans. For instance, metformin administration may mimic a dietary restriction (DR) metabolism (Onken and Driscoll, 2010). In addition, alteration of methionine metabolism in C. elegans has been shown to play a partial role (Cabreiro et al., 2013). Recently, metformin has been shown to inhibit mTORC1 due to restricted transit of RagA-RagC GTPase through nuclear pore complex (NPC) (Wu et al., 2016). It is possible that these observations reflect downstream consequences of a primary action of metformin. Therefore, understanding its direct mechanism of action worth further investigation.
Elucidating metformin’s mode of action will significantly boost its application to target human aging and prevent age-related diseases.

Results

**Metformin coordinates mTORC1 and AMPK through the lysosomal pathway**

Intrigued by the discoveries that mTORC1 and AMPK share the common activator, v-ATPase-Ragulator complex (Zhang et al., 2014), and that metformin may directly act on the lysosomal pathway to promote AMPK activation (Zhang et al., 2016), we sought to set up a pure in vitro reconstitution system to explore the mechanism of metformin’s action (Figure 1). We stably expressed LAMP1-RFP-FLAG in HEK293T cells to label lysosomes (Figure 1A) and performed FLAG pull-down to enrich lysosomes. The purity of lysosome preparation was confirmed by immunoblotting to test for the absence of early endosome, mitochondria, ER or nuclei (Figure 1B). Immuno-purified Raptor was then provided to the lysosomes. Upon amino acids stimulation, significant portion of Raptor accumulated on the lysosome (Figure 1C,F), indicating the activation of mTORC1 pathway. We then supplemented Concanavalin A (Con A), a v-ATPase inhibitor, or Metformin (Met) to the reconstitution system. Addition of Con A or metformin dissociated Raptor from the lysosome (Figure 1D,G). It has been proposed that AMPK might directly phosphorylates Raptor and thus inhibits mTORC1 (Gwinn et al., 2008). To test if metformin’s effect on mTORC1 inhibition requires AMPK or not, we repeated the in vitro experiments in AMPK knockout MEF cells, and still observed the dissociation of Raptor (Figure 1—figure supplement 1). Taken together, these results suggest that metformin inhibits mTORC1 through the lysosomal pathway independent of AMPK, possibly mimicking Con A to inhibit v-ATPase. Lastly, we provided purified AXIN and LKB1 to the in vitro system. Immuno-purified LKB1 forms a complex with endogenous STRAD and MO25, two proteins essential for optimal LKB1 activity (Figure 1—figure supplement 2). Consistent with previous findings, AXIN/LKB1 were recruited to metformin- or Con A-treated lysosomes, and were sufficient to phosphorylate endogenous AMPK in an amino acid-independent manner (Figure 1E,H) (Zhang et al., 2016; Zhang et al., 2013).

It has been proposed that metformin might change the AMP/ATP ratio through inhibition of mitochondrial ETC complex I, ultimately resulting in AMPK activation (El-Mir et al., 2000; Foretz et al., 2014; Owen et al., 2000). To test if metformin could inhibit mitochondrial function and therefore activate mitochondrial stress response, we treated *C. elegans* hsp-6p::gfp reporter strain with metformin, or rotenone, a well-known mitochondrial ETC complex I inhibitor. Unlike rotenone, metformin treatment showed no reporter activation (Figure 1—figure supplement 3A,B). It should be noted that others have reported that metformin inhibits ETC complex I through a mechanism distinct from that of rotenone: metformin treatment increases ROS production, whereas rotenone decreases it (De Haes et al., 2014). Because our in vitro reconstitution system excludes mitochondrial contaminants, it highly suggests that metformin inhibits mTORC1 and activates AMPK mainly through the lysosomal pathway. Lastly, we directly measured the metformin’s effect on lysosomal function with the use of a cathepsin assay. Cathepsin is a class of cysteine proteinase localized within lysosomes. A cathepsin assay is a fluorescence-based assay that cleaves cathepsin’s substrate to release fluorescence. Consistent with our idea, metformin administration indeed impaired lysosomal function (Figure 1—figure supplement 3C,D).

**Metformin inhibits TORC1 pathway in *C. elegans***

Because our in vitro biochemical results suggested that metformin might act on the v-ATPase-Ragulator complex of the lysosomal pathway to coordinate mTORC1 inhibition and AMPK activation, we next tested if metformin promotes lifespan extension in *C. elegans* due to similar mechanisms. To confirm that metformin also inhibits TORC1 in *C. elegans*, we first examined phosphorylation status of RSKS-1, the human ribosomal protein S6 kinase B1 (S6K) homolog in *C. elegans*. We used an antibody that specifically detects Thr-389, a highly conserved phosphorylation site among species (Figure 2—figure supplement 1A). This antibody was validated with the used of rsk-1 RNAi (Figure 2—figure supplement 1B). Notably, metformin treatment significantly decreased the level of RSKS-1 phosphorylation (Figure 2A,B), suggesting an inhibition of TORC1 pathway. We also
Figure 1. Metformin coordinates mTORC1 and AMPK on purified lysosome. (A) HEK293T cells stably expressing LAMP1-RFP-FLAG were mechanically broken. (B) Lysosomes were purified through immunoprecipitation (Organelle markers: LAMP2, lysosome; EEA1, early endosome; Prohibitin, mitochondria; PDI, ER; Histone H3, nucleus). (C) Lysosomal accumulation of purified Myc-raptor upon amino acids stimulation. (D–E) Lysosomal disassociation of Myc-raptor (D), lysosomal accumulation of Myc-AXIN/LKB1 and phosphorylation of AMPK (E) upon Concanamycin A (Con A) or Metformin (Met) treatment. (F–H) Quantifications of immunoblots in (C–E). Immunoblots of Myc-Raptor, Myc-AXIN and Myc-LKB1 were normalized to that of LAMP-RFP-FLAG, and immunoblots of p-AMPK were normalized to that of AMPK. Relative intensities of three independent biological replicates are shown as mean ± SEM. ns, no significant difference; *p<0.05; **p<0.01; ***p<0.001.

DOI: https://doi.org/10.7554/eLife.31268.003

The following figure supplements are available for figure 1:

Figure supplement 1. Metformin inhibits mTORC1 independent of AMPK.
DOI: https://doi.org/10.7554/eLife.31268.004

Figure supplement 2. Purified Myc-LKB1 forms a complex with endogenous STRAD and MO25.
DOI: https://doi.org/10.7554/eLife.31268.005

Figure supplement 3. Metformin targets lysosome in C.elegans.
DOI: https://doi.org/10.7554/eLife.31268.006
tested the subcellular localization of HLH-30, an ortholog of transcription factor EB (TFEB) that translocates to the nucleus upon TORC1 inhibition (Lapierre et al., 2013; Perera and Zoncu, 2016; Settembre et al., 2011). Indeed, HLH-30 translocated to the nucleus in the tail region of C. elegans upon metformin administration (Figure 2C,D). Once in the nucleus, HLH-30 regulates the transcription of genes related to autophagy, lysosome function and lipid hydrolysis (Lapierre et al., 2013; O’Rourke and Ruvkun, 2013). Consistently, we also observed up-regulation of transcript levels of hlh-30 downstream targets upon metformin treatment (Figure 2E). Taken together, these results indicate that metformin inhibits TORC1 pathway in C. elegans.

We also tested if metformin’s effect on TORC1 inhibition requires AMPK in C. elegans. Consistent with our results in AMPK−/− MEF cells (Figure 1—figure supplement 1), metformin treatment of aak-2 (Ce.AMPK) loss-of-function mutants was still able to drive HLH-30 nuclear accumulation (Figure 2—figure supplement 2A,B) and elevate the expression of HLH-30 target genes (Figure 2—figure supplement 2C).
Metformin extends healthspan partially through TORC1 inhibition

Inhibition of TORC1 has been shown to result in lifespan extension (Jia et al., 2004; Vellai et al., 2003); also reviewed by Zoncu et al., 2011). To distinguish if metformin induces lifespan extension solely through Ce.TOR inhibition, or the activation of Ce.AMPK also plays a role, we performed lifespan analysis on control worms or daf-15 heterozygous mutants in the presence or absence of metformin (Figure 3—figure supplement 1A). Compared with the control worms, daf-15 heterozygous mutants had a longer lifespan and a decreased level of RSKS-1 phosphorylation (Figure 3—figure supplement 1B,C), indicating that TORC1 inhibition extends C. elegans lifespan. More importantly, metformin treatment greatly extended the lifespan of daf-15 heterozygous mutants (Figure 3A).

To investigate the metabolic effects of metformin on daf-15 heterozygous mutants, we fed L4 worms with metformin and conducted Oil-Red-O (ORO) staining to detect neutral fat levels (Figure 3—figure supplement 1D). Similar to wild type animals, metformin administration further decreased neutral fat level in daf-15 heterozygous mutants (Figure 3B,C). Aged worms start to show muscle deterioration and decrease locomotion rates (Huang et al., 2004; Onken and Driscoll, 2010). Metformin treatment significantly increased the locomotory ability (counted by the average bends of worm body per 60 s) and reduced age pigments of wild type worms and daf-15 heterozygous mutants (Figure 3—figure supplement 1D, and Figure 3D,E), indicating that metformin also improves fitness of daf-15 heterozygous mutants.

Figure 3. Metformin extends healthspan partially due to TORC1 inhibition. (A) Lifespan analysis of control worms or daf-15 heterozygous mutants in the presence or absence of metformin. (B) Representative images of Oil-Red-O (ORO) staining of control worms or daf-15 heterozygous mutants in the presence or absence of metformin. (C) Quantification of (B). Error bars represent mean ± SEM of 3 independent biological replicates (sample size: n ≥ 40 worms). (D–E) Locomotion (D) and age pigments (E) were measured in control worms or daf-15 heterozygous mutants in the presence or absence of metformin. Mean ± SEM of 3 independent biological replicates are shown (sample size: n ≥ 20 worms for locomotion assay; n ≥ 40 worms for age pigments assay). (F) Representative fluorescent images of HLH-30 nuclei localization in control worms or daf-15 heterozygous mutants in the presence or absence of metformin. Arrows indicate nuclear localized HLH-30::GFP. (G) Quantification of (F). Percentage of unc-24/+; HLH-30::GFP or unc-24/daf-15; HLH-30::GFP worms with nuclear accumulation of HLH-30 were counted. Error bars represent mean ± SEM of 3 independent biological replicates. (sample size: n ≥ 40 worms) (H) Representative western blotting of AAK-2 phosphorylation in the presence or absence of metformin. (I) Quantification of (H). 300 worms were pooled in each protein sample. Error bars represent mean ± SEM of 3 independent biological replicates. ns, no significant difference; *p<0.05, **p<0.01, ***p<0.001. DOI: https://doi.org/10.7554/eLife.31268.010

The following figure supplements are available for figure 3:

Figure supplement 1. Deletion of daf-15 suppresses TORC1 activity.
DOI: https://doi.org/10.7554/eLife.31268.011

Figure supplement 2. Metformin promotes longevity through a pathway additive to TORC1 inhibition.
DOI: https://doi.org/10.7554/eLife.31268.012
Metformin’s beneficial effect on lifespan and fitness of *daf-15* heterozygous mutants could be due to a pathway additive to that of TORC1 inhibition (e.g. AMPK pathway), or simply due to a further suppression of TOR activity in *daf-15* heterozygous mutants. To test if metformin could further inhibit TORC1 activity in *daf-15* heterozygous mutants, we compared HLH-30 nuclear localization between control animals and *daf-15* heterozygous mutants in the presence or absence of metformin treatment. We found that in *daf-15* heterozygous mutants, significant portion of HLH-30 already localized in the nucleus, suggesting an inhibition of TORC1 activity. More importantly, metformin administration increased HLH-30 nuclear localization in control worms, but not in *daf-15* heterozygous mutants (*Figure 3F,G*). In addition, we performed lifespan experiments with loss-of-function mutants of known downstream targets of TORC1, which have been reported to mediate TORC1 inhibition-induced longevity (Robida-Stubbs et al., 2012). We found that metformin could still extend lifespans of *hlh-30,pha-4* or *skn-1* mutants (*Figure 3—figure supplement 2*). These results suggest that metformin may act on a pathway additive to that of TORC1 inhibition to confer fitness benefit. Given that metformin activated AMPK in *daf-15* heterozygous mutant to the same level as that in the control worms (*Figure 3H,I*), it is likely that metformin promotes longevity also through activation of AMPK.

**Metformin extends lifespan through lysosome-dependent activation of AMPK**

v-ATPase-Ragulator complex may function as lysosomal acceptor for AXIN/LKB1, which translocate to lysosome and activate AMPK upon metformin treatment (*Figure 1B*). Thus, to test the lysosome-dependent AMPK activation for metformin-induced lifespan extension, we first performed lifespan analysis on *vha-3* (subunit of v-ATPase V0 domain), *vha-12* (subunit of v-ATPase V1 domain), *lmtr-3* (LAMTOR 3 subunit of Ragulator) and *lmtr-2* (LAMTOR 2 subunit of Ragulator) loss-of-function mutants (*Figure 4—figure supplement 1 and Figure 4A*). VHA-3, VHA-12, LMTR-3 and LMTR-12 all localized on the lysosomes of *C. elegans*, as they have similar staining pattern with lysosomal marker LMP-1 (*Figure 4—figure supplement 2*). All these four mutants had impaired lysosomes, which could be rescued with the expression of corresponding gene (*Figure 4—figure supplement 3*). *vha-3* and *vha-12* mutants had longer lifespans compared with wild type animals, whereas lifespan of *lmtr-2* or *lmtr-3* mutants was comparable to that of the wild type animals (*Figure 4B and C and Figure 4—figure supplement 4A and B*). Lifespan extension in *vha-3* and *vha-12* mutants might be due to Ce.TOR inhibition, because v-ATPase is required for the spatial regulation and subsequent activation of TORC1. Consistently, failure of *lmtr-3* or *lmtr-2* to induce lifespan extension suggested that Ce.TOR pathway was not inhibited under *lmtr-3* or *lmtr-2* deficiency. Indeed, RNAi knockdown of vha-3 but not lmtr-3, was sufficient to induce the nuclear accumulation of HLH-30 and activate HLH-30 downstream targets (*Figure 4—figure supplement 4C and D*, and *Figure 4D–F*). In addition, knocking down of vha-3 but not lmtr-3, decreased the level of RSKS-1 phosphorylation (*Figure 4G and H*).

More importantly, metformin administration could not further induce the lifespan extension, nor AAK-2 activation in v-ATPase mutants *vha-3* and *vha-12*, or Ragulator mutants *lmtr-3* and *lmtr-2* (*Figure 4B–C and I–J and Figure 4—figure supplement 4A, B, E and F*), suggesting that metformin’s effect on lifespan extension may also depend on the lysosomal pathway of AMPK activation. It should be noted that metformin even shortens the lifespan of *lmtr-3* or *lmtr-2* mutants (*Figure 4C and Figure 4—figure supplement 4B*). However, fractions of censored animals were not increased in metformin-treated *lmtr-3* or *lmtr-2* mutants (*Figure 4—figure supplement 4G*), suggesting that metformin did not make the mutants sick.

AXIN is a scaffold protein required for lysosomal localization of LKB1 and lysosome-dependent activation of AMPK (Zhang et al., 2016; Zhang et al., 2013). We could not successfully express AXL-1 (*C. elegans* ortholog of AXIN) with fluorescent tag in worms and test for its subcellular localization. Therefore, we expressed EGFP-tagged AXL-1 in mammalian cells and showed that AXL-1 only localized on the lysosome upon metformin treatment (*Figure 5A*). Consistently, without metformin administration, axl-1 mutant alone did not perturb lysosomal function (*Figure 5B*). We then examined the role of AXIN in metformin-induced lifespan extension. Metformin treatment failed to activate AAK-2 (*C.eAMPK*) in axl-1 mutant (*AXIN-deficient animals*) (*Figure 5C,D*). Consistently, metformin was no longer able to extend lifespan of axl-1 mutant animals (*Figure 5E*). Similar to axl-1, metformin could not extend lifespan of *par-4* (*C. elegans* ortholog of LKB-1) mutants as well.
Figure 4. Metformin extends lifespan through v-ATPase-Ragulator-dependent activation of AMPK. (A) A scheme depicting genes within C. elegans TORC1 and AMPK pathways. (B–C) Lifespan analysis of wild type, vha-3 (B), or lmtr-3 (C) animals in the presence or absence of metformin. (D) Representative fluorescent images of HLH-30 nuclear localization in worms administered with control, vha-3 or lmtr-3 RNAi. (E) Quantification of (D), percentage of worms with HLH-30 nuclear accumulation. Mean ± SEM of 3 independent biological replicates are shown (sample size: n ≥ 40 worms). (F) Q-PCR analysis of HLH-30 target genes in worms administered with control, vha-3 or lmtr-3 RNAi. ~300 worms were collected for each mRNA sample. Data from 3 independent biological replicates are shown as mean ± SEM. (G) Representative immunoblots of RSKS-1 phosphorylation in worms administered with control, vha-3 or lmtr-3 RNAi. (H) Quantification of (G). ~300 worms were pooled in each protein sample. Relative intensities of 3 independent biological replicates are shown as mean ± SEM. (I) Representative immunoblots of AAK-2 phosphorylation in wild type, vha-3 or lmtr-3 mutants, in the presence or absence of metformin. (J) Quantification of (I). ~300 worms were collected in each protein sample. Relative intensities of 3 independent biological replicates are shown as mean ± SEM. ns, no significant difference; *p<0.05; **p<0.01; ***p<0.001.

DOI: https://doi.org/10.7554/eLife.31268.013

The following figure supplements are available for figure 4:

Figure supplement 1. Genotyping of v-ATPase and Ragulator mutants.
DOI: https://doi.org/10.7554/eLife.31268.014

Figure supplement 2. Lysosomal localization of C.elegans v-ATPase-Ragulator proteins.
DOI: https://doi.org/10.7554/eLife.31268.015

Figure supplement 3. Mutation of v-ATPase or Ragulator perturbs lysosomal function in C.elegans.
DOI: https://doi.org/10.7554/eLife.31268.016

Figure supplement 4. Metformin extends lifespan through v-ATPase-Ragulator-dependent AMPK activation.
DOI: https://doi.org/10.7554/eLife.31268.017
Metformin attenuates age-related fitness decline through lysosome-dependent activation of AMPK

It has been shown that metformin triggers a dietary restriction-like state and extends C. elegans lifespan through AMPK pathway (Onken and Driscoll, 2010). Indeed, metformin administration induced a dietary restriction-like state to decrease neutral fat level in wild type animals (Figure 6A, B). Conversely, vha-3 (v-ATPase V0), lmtr-3 (Ragulator) and axl-1 (AXIN) mutants retained the same levels of ORO staining in the presence or absence of metformin (Figure 6A,B), suggesting that the dietary restriction-like state triggered by metformin requires the lysosome-dependent activation of AMPK.

Metformin treatment also significantly increased the locomotory ability and lowered age pigments of wild type worms (Figure 6C and G), indicating that metformin promotes youthful physiology and fitness of C. elegans. Strikingly, mutation of vha-3, lmtr-3 or axl-1 impaired metformin’s effects on locomotion and age pigments (Figure 6D–G), suggesting that lysosome-dependent activation of AMPK is also required for metformin-attenuated fitness decline in aged animals.

DOI: https://doi.org/10.7554/eLife.31268.018

(Figure 5F) (Onken and Driscoll, 2010). Taken together, these genetic evidences indicate that v-ATPase-Ragulator-AXIN-LKB1-based lysosome pathway is required for the metformin’s effects of lifespan extension.
Discussion

Using a pure in vitro reconstitution system that excludes mitochondria, we showed that metformin coordinates mTORC1 inhibition and AMPK activation through lysosomal pathway. We further employed genetic manipulation to show that metformin extends *C. elegans* lifespan and attenuates age-related fitness decline via similar mechanism that requires v-ATPase-Ragulator-AXIN/LKB1 of the lysosomal pathway (Figure 6H). Metformin may function by targeting and priming v-ATPase-Ragulator complex on lysosome membrane, which serves as a hub to coordinate mTORC1 and AMPK pathways and govern metabolic programs. It is possible that metformin administration might result in a conformational change of v-ATPase-Ragulator complex, which dissociates mTORC1 from lysosome and allows the docking of AXIN/LKB1 for AMPK activation (Figure 6—figure supplement 1).
It will be of particular interest in the future to test if v-ATPase is the direct target of metformin. Elucidating the molecular mechanism of metformin-mediated lifespan extension will boost its application in the treatment of human aging and age-related diseases.

Materials and methods

Cell culture
HEK293T cells used for protein purification, virus packaging and stable cell line generation, and AMPKα1/2 double knockout (DKO) MEF cells used for stable cell line generation were cultured with DMEM high glucose medium (HyClone, SH30243.01), supplemented with 10% FBS (Gibico, 10099–141) and 1% Penicillin/Streptomycin (HyClone SV30010). 293T HEK cells were obtained from ATCC, not authenticated, and mycoplasma negative. AMPKα1/2 double knockout (DKO) MEF cells were provided by Dr. Benoit Viollet, validated by immunoblotting and determined as mycoplasma negative.

Generation of stable cell line
HEK293T cells and AMPKα1/2 DKO MEF cells stably expressing LAMP1-RFP-FLAG fusion protein, or HEK293T cells stably expressing AXL-EGFP and LAMP1-RFP-FLAG were generated with the lentiviral packaging and infection system. 0.8 × 10⁶ HEK293T cells were seeded into one well of a 6-well-plate and cultured with 2 ml medium. After about 20 hr, 0.75 ug pMDLg/pRRE, 0.3 ug pRSV-Rev, 0.45 ug pCI-VSVG and 1.5 ug pLJM1-LAMP1-RFP-FLAG (addgene) plasmids were co-transfected into cells. Medium was changed 8 hr after transfection. Cells were then cultured for additional 24 hr to allow virus production, and 2 ml medium containing virus was harvested (virus packaging). 300 ul virus-containing medium was diluted with 900 ul fresh medium, and added into one well of a 12-well-plate containing HEK293T cells or AMPKα1/2 DKO MEF cells at ~40% confluence (virus infection). Several hours after infection, cells stably expressing LAMP1-RFP-FLAG were checked by RFP fluorescence. ~100% HEK293T cells or ~20% AMPKα1/2 DKO cells contain RFP signal. HEK293T LAMP1-RFP-FLAG stable cell line was then infected by virus carrying AXL-EGFP to generate double stable cell line.

Protein purification
Recombinant proteins Myc-LKB1 (human), Myc-AXIN (mouse), and Myc-Raptor (human) were immunopurified from HEK293T cells. For purification of each protein, 20 × 15 cm dishes of HEK293T cells were cultured until 80% confluence. 28 ug of plasmid was transfected to each dish of cells with Lipofectamine 3000 Transfection Reagent. Medium was changed 8 hr after transfection. After additional 24 hr, medium was carefully discarded and cells were rinsed with PBS. 1.5 ml of TX-100 lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 2.5 mM Sodium pyrophosphate, 1 mM β-glycerophosphate, 1% Triton X-100, PH = 7.4) supplemented with protease inhibitors was added to each dish of cells. Cells were incubated on ice for 10 min, and then scraped off the dishes. Cell lysate was sonicated at 60% Ampl for 5 × 30 s (SONICS VCX 130 PB, UK), and centrifuged at 4°C, 10000 rpm for 10 min. Supernatant was mixed with 500 ul Myc agarose beads, and rotated overnight at 4°C. Beads were washed three times with TX-100 lysis buffer and three times with fractionation buffer (50 mM KCl, 90 mM K-Gluconate, 1 mM EGTA, 5 mM MgCl₂, 50 mM Sucrose, 5 mM Glucose, 20 mM HEPES, pH = 7.4, 2.5 mM ATP and protease inhibitors were added right before usage), and resuspended in 800 ul of fractionation buffer, followed by addition of 10 ul 10 mg/ml Myc peptide. After rotating at 4°C for 4 hr, Myc tagged protein in 800 ul fractionation buffer was harvested, followed by addition of 160 ul glycerol, and stored at −20°C.

Lysosome purification and in vitro reconstitution
LAMP1-RFP-FALG stable cells were cultured until confluence. For each sample, 1 × 10 cm dish of HEK293T cells or 5 × 10 cm dishes of MEF AMPKα1/2 DKO cells were scraped off the plate, and pelleted at 1000 rpm, room temperature for 3 min. Cell pellet was washed once with fractionation buffer, resuspended in 0.8 ml fractionation buffer, and mechanically broken by spraying six times through a 23G needle attached to a 1 ml syringe. Broken cells were spun down at 2000 g for 10 min at 4°C to pellet the nuclei, yielding a post-nuclei supernatant (PNS). The PNS was diluted to 2 ml.
with fractionation buffer, and subjected to immunoprecipitation with 50 ul FLAG magnetic beads (60% slurry) for 2 hr at 4°C on a rotator. Lysosome on beads was washed three times and resuspended in 300 ul fractionation buffer, supplemented with 1x amino acids (combining 50x Gln-free MEM amino acids mixture with 100x Glutamine solution from Gibico), 250 uM GTP and 100 uM GDP. Lysosome was then rotated at 37°C, 650 rpm on a Thermomixer (Eppendorf, Germany) for 15 min (activation step for Raptor binding). 40 ul of purified Myc-Raptor protein was added, and the system was shaken for additional 25 min (lysosome binding step for Raptor). 10 uM Concanamycin A (ConA) or 300 uM Metformin (Met) was then provided into the reaction system, and incubated for 30 min (Raptor off lysosome membrane step). Lysosome coated magnetic beads were isolated from the reaction system, resuspended with 300 ul fractionation buffer supplemented with 80 ul purified Myc-AXIN and 20 ul purified Myc-LKB1 (formed a complex with endogenous STRAD and MO25), and then shaken on Thermomixer for 25 min (AXIN/LKB1 lysosome translocation and AMPK activation step).

**Western blotting**

For in vitro reconstitution, each sample was prepared with 30 ul 2x laemmli sample buffer. Purified lysosomes were checked with LAMP2 (abcam ab25631), EEA1 (CST 3288), Prohibitin (Santa Cruz 28259), PDI (Santa Cruz 20132), and Histone H3 (Huaxingbio, HX1850) antibodies. Myc tagged proteins were detected with anti-Myc antibody (ImmunoWag YM3203). LAMP1-RFP-FLAG labeled lysosomes were probed with Flag antibody (Sigma F7425). T172 site phosphorylated AMPKα subunit and total AMPKα subunit were detected with p-AMPKα (CST 2535) and AMPKα (CST 2532) antibodies respectively. STRAD (Santa Cruz sc-34102) and MO25 (CST 2716 s) antibodies were used to detect Myc-LKB1-STRAD-MO25 complex.

For detection of AAK-2 or RSKS-1 phosphorylation, worms at indicated stage were lysed with 2x laemmli sample buffer equal to the volume of worm pellet. AAK-2 phosphorylation was probed with human p-AMPKα (T172) antibody (CST 2535). RSKS-1 phosphorylation was probed with human p-S6K1 (T389) antibody (CST 9205). Tubulin (abcam ab6161) was used as loading control.

**Nematode culture**

Detailed information of Caenorhabditis elegans strains used in this paper was provided in Supplementary file 1–2. Worms were maintained on nematode growth medium (NGM) plate with OP50 as standard food. All worms, except for pha-4 and par-4 mutants, were cultured at 20°C. Metformin was added into molten agar at the concentration of 50 mM while preparing plates. Rotenone stock was prepared at 10 ug/ul in DMSO. 1 ul rotenone stock was diluted with 300ul M9 and added directly onto a 6 cm NGM plate and hood-dried.

RNA interference (RNAi) clones were grown at 37°C overnight in LB containing 50 ug/ml carbenicillin. 200 ul bacteria were then seeded onto NGM containing 1 mg/ml IPTG and 50 ug/ml carbenicillin, hood-dried and cultured overnight to induce dsRNA expression. L1 stage Worms were then seeded onto bacteria lawn, and raised until L4 stage for efficient knockdowns.

**Lifespan assays**

~100 L4 stage (day 0 for lifespan assays) worms (except for lmtr-2, lmtr-3, par-4 and pha-4) were transferred to plates with or without metformin. For lmtr-2 or lmtr-3 mutant strain, ~250 worms were used, due to high percentage of censored worms. For par-4 mutant, worms were cultured at 15°C until L4 stage (day 0 for lifespan assays), and ~100 worms were transferred to 25°C for lifespan assay. For pha-4 mutant, worms were cultured at 25°C until day 1 adult (day 0 for lifespan assays), and ~100 worms were transferred to 15°C for lifespan assay. FUDR was used to prevent reproduction. Worms were transferred to new plates and counted every other day. FUDR was omitted after day 12. Animals that did not move when gently prodded were scored as dead. Animals that crawled off the plate or died from vulva bursting were censored.

**Oil-Red-O (ORO) staining**

Worms were washed with 1x PBS and resuspended in 120 ul 1x PBS, followed by addition of 120 ul 2x MRWB buffer (160 mM KCl, 40 Mm NaCl, 14 mM Na₂EGTA, 1 mM Spermidine-HCl, 0.4 mM Spermine, 30 mM Na-PIPES, 0.2% β-mercaptoethanol, PH = 7.4) containing 2% PFA. Samples were
fixed by gently rocking at room temperature for 1 hr. Worms were then washed with 1x PBS to remove PFA, and resuspended in 300 μl 60% isopropanol to dehydrate for 15 min at room temperature. Worms were pelleted and resuspended with 1 ml 60% ORO solution, and rotated overnight at room temperature (Preparation of 60% ORO solution: commercial liquid ORO stain was diluted to 60% with H2O, rock overnight at room temperature, and filtrated with 0.22 um filter right before usage). Worms were settled and ORO staining solution was removed. 200 ul 1x PBS (with 0.01% triton X-100) was added to resuspend the worms. Worms were quickly transferred on to a glass slide and photographed with Zeiss Imager M2 microscope.

**Locomotion assay**
Worms were transferred into a drop of M9 on a glass slide, and filmed with Zeiss Imager M2 microscope. Body bends were counted by reviewing each frame of the 60 s film.

**Age pigment fluorescence detection**
Worms were mounted onto an agarose pad attached to a glass slide and photographed with Zeiss Imager M2 microscope. Fluorescence intensity was counted by Image J.

**Lysosome function assay**
Magic Red stain (ImmunoChemistry Technologies #938, Bloomington, Minnesota) can be cleaved by cathepsin B, and generate red fluorescent substrate in functional lysosomes. Magic Red stain was prepared in 260x DMSO stock following the manufacturer’s instructions. 3.8 ul stock was 5x diluted with M9, spread onto a well of 24-well-plate containing 1 ml NGM, and dried in hood. For metformin’s effect on lysosomal function, wild type L1 stage worms were raised to L4 stage on control or metformin NGM plate containing Magic Red stain. For cathepsin assay, L4 stage worms were transferred onto Magic Red containing plate and cultured overnight. Worms were photographed with Zeiss Imager M2 microscope and quantified by Image J.

**Lysosomal localization assay**
The longest CDS sequences of *lmp-1*, *vha-3/12* and *lmtr-2/3* were amplified from worm genomic DNA, and cloned into expression vector containing *rpl-28* promoter (whole body expression). LMP-1::GFP was initially integrated into *C. elegans* genome through UV irradiation, and worms were backcrossed for six times. mCherry-VHA-3/12 or mCherry-LMTR-2/3 was then injected into worms expressing LMP-1::GFP. Worms were photographed by Zeiss Imager M2 microscope. The longest CDS sequence of *axl-1* was amplified from worm genomic DNA and cloned into mammalian expression construct containing CMV promoter and C-terminal EGFP tag. HEK293T cells stably expressing AXL-1-EGFP and LAMP-1-RFP-FLAG were generated as described above. Cells were imaged by Zeiss LSM710 confocal microscope.

**Reporter assays**
*hsp-6p::gfp* reporter worms were photographed by Zeiss Imager M2 microscope and the fluorescent intensity was quantified by Image J. *hlh-30p::hlh-30::gfp* reporter worms were photographed by Zeiss Imager M2 microscope and percentage of worms with nuclear localization of HLH-30 was counted. To monitor HLH-30 nuclear localization in control or *daf-15* heterozygous mutant, we injected *hlh-30p::hlh-30::gfp* construct into control or *daf-15* heterozygous mutant respectively. Worms were photographed by Zeiss Imager M2 microscope. Percentage of worms with nuclear localization of HLH-30 was counted.

**RNA extraction and Q-PCR**
Worms were washed off plates with M9 and resuspended with TRIzol Reagent and frozen by liquid nitrogen. Total RNA was isolated by chloroform extraction and isopropanol precipitation. 200 ng total RNA was used for reverse transcription with One-Step cDNA Synthesis Kit (TransGen Biotech, China). Real-time PCR was carried out using SYBR GREEN PCR Master Mix (Biorad, Hera Claes, California). Quantifications of transcripts were normalized to *rpl-32.*
Q-PCR primers

| Target gene | Forward primer | Reverse primer |
|-------------|----------------|---------------|
| rpl-32      | AGGGAATGGATAACCGTGTCGCA | TGTAGGACTGCATAGGAGCATGT |
| hlh-30      | CTCATCGGCGGGCGCTCATC | AGAACCGCATGGGAGGTGAGG |
| lgg-1       | ACCCAGACCGTTATTCCAGTG | ACGAAGTTGGATGCCTTTTC |
| lgg-2       | CTGCCTTATTCCAGTACCCGAG | CATGAAATTTGACACCATTGAGC |
| atg-16.2    | ATGTCATATCTTGTAGTCCGGG | ACGTTGCACTCTGAAGAGCGTG |
| atg-18      | AAATGGAACATCGGCTTTTG | TGATAGCATCGAACCATCCA |
| sul-2       | ATGGCGGCAAAGGACACCCG | GCCATTTTCCAACCATGCGAGTTCG |
| ctsa*       | TTCTCCTCGAGGCGGGAT | TCCAACCGCAATTGGGGACTC |
| cpr-1       | CGCCAGGGCAAGCAGTTCGGA | ACCGGGCCCTTTCGGCGAC |
| lipl-1      | GTGACATTGTTTTTCCATTAT | AGCAAATAAACCGACCAC |
| lipl-2      | AATAAGGATCTATCCATTGAA | GATAAATCTGTTTTTCCATAA |
| lipl-3      | ATGGGCAGGCCAATCCACCA | AGTGTCTGGCGAATTATA |

Acknowledgements

We thank Dr. Sheng-Cai Lin for his generous gifts of plasmids and reagents. We thank Dr. Benoit Viollet for providing us AMPK knockout cells. Several C. elegans strains used in this work were provided by CGC, which is supported by the NIH-Officer of Research Infrastructure Programs, and the Japanese National BioResource Project. The work is supported by grants from the National Natural Science Foundation of China (grants 31422033 and 31471381) and the Ministry of Science and Technology of China (973 grants 2013CB910104), the Young Thousand Talents Program of China, and Peking-Tsinghua Center for Life Sciences awarded to YL.

Additional information

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Jie Chen, Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft, Project administration; Yuhui Ou, Data curation, Validation, Investigation; Yi Li, Validation, Investigation; Shumei Hu, Li-Wa Shao, Investigation; Ying Liu, Conceptualization, Supervision, Funding acquisition, Visualization, Methodology, Writing—original draft, Writing—review and editing
Author ORCIDs
Ying Liu http://orcid.org/0000-0002-3328-026X

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.31268.026
Author response https://doi.org/10.7554/eLife.31268.027

Additional files
Supplementary files

- Supplementary file 1. Strains and RNAi used in this study.
  DOI: https://doi.org/10.7554/eLife.31268.021

- Supplementary file 2. Lifespan analysis of metformin’s effect on daf-15 heterzogous mutants.
  DOI: https://doi.org/10.7554/eLife.31268.022

- Supplementary file 3. Lifespan analysis of metformin’s effect on mutants of TORC1 downstream genes.
  DOI: https://doi.org/10.7554/eLife.31268.023

- Supplementary file 4. Lifespan analysis of metformin’s effect v-ATPase, Ragulator, AXIN/LKB1 mutants.
  DOI: https://doi.org/10.7554/eLife.31268.024

- Transparent reporting form
  DOI: https://doi.org/10.7554/eLife.31268.025

References

Anisimov VN, Berstein LM, Egornin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV. 2008. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7:2769–2773. DOI: https://doi.org/10.4161/cc.7.17.6625, PMID: 18728386

Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. 2012. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 150:1196–1208. DOI: https://doi.org/10.1016/j.cell.2012.07.032, PMID: 22980980

Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. 2016. Metformin as a tool to target aging. Cell Metabolism 23:1060–1065. DOI: https://doi.org/10.1016/j.cmet.2016.05.011, PMID: 27304507

Burkewitz K, Zhang Y, Mair WB. 2014. AMPK at the nexus of energetics and aging. Cell Metabolism 20:10–25. DOI: https://doi.org/10.1016/j.cmet.2014.03.002, PMID: 24726383

Cabreiro F, Au C, Leung KY, Vergara-irigary N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. 2013. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153:228–239. DOI: https://doi.org/10.1016/j.cell.2013.02.035, PMID: 23540700

Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, Radovick S, Wondisford FE, He L. 2014. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). Journal of Biological Chemistry 289:20435–20446. DOI: https://doi.org/10.1074/jbc.M114.567271, PMID: 24928508

De Haes W, Frøoninckx L, Van Assche R, Smolders A, Depuydt G, Billen J, Braeckman BP, Schoofs L, Temmerman L. 2014. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. PNAS 111:E2501–E2509. DOI: https://doi.org/10.1073/pnas.1321776111, PMID: 24889636

Dibble CC, Manning BD. 2013. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nature Cell Biology 15:555–564. DOI: https://doi.org/10.1038/nclb2763, PMID: 2328461

El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 275:223–228. DOI: https://doi.org/10.1074/jbc.275.1.223, PMID: 10616708

Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. 2014. Metformin: from mechanisms of action to therapies. Cell Metabolism 20:953–966. DOI: https://doi.org/10.1016/j.cmet.2014.09.018, PMID: 25456737

Fryer LG, Parbu-Patel A, Carling D. 2002. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways, Journal of Biological Chemistry 277:25226–25232. DOI: https://doi.org/10.1074/jbc.M202489200, PMID: 11944296

Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 30:214–226. DOI: https://doi.org/10.1016/j.molcel.2008.03.003, PMID: 18439900

Chen et al. eLife 2017;6:e31268. DOI: https://doi.org/10.7554/eLife.31268
Hardie DG, Ross FA, Hawley SA. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology 13:251–262. DOI: https://doi.org/10.1038/nrm3311, PMID: 22436748

Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. 1996. Characterization of the AMP-activated protein kinase cascade from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. Journal of Biological Chemistry 271:27879–27887. DOI: https://doi.org/10.1074/jbc.271.44.27879, PMID: 8910387

Hawley SA, Gadalla AE, Olsen GS, Hardie DG. 2002. The anti-diabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425. DOI: https://doi.org/10.2337/diabetes.51.b.2420, PMID: 12145153

He L, Wondisford FE. 2015. Metformin action: concentrations matter. Cell Metabolism 21:159–162. DOI: https://doi.org/10.1016/j.cmet.2015.01.003, PMID: 25651170

Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoehaj G, Saghatelian A, Shaw RJ, Manning BD. 2017. Metformin inhibits hepatic mtorc1 signaling via dose-dependent mechanisms involving ampk and the tsc complex. Cell Metabolism 25:463–471. DOI: https://doi.org/10.1016/j.cmet.2016.12.009, PMID: 28089566

Huang C, Xiong C, Kornfeld K. 2004. Measurements of age-related changes of physiological processes that predict lifespan of Caenorhabditis elegans. PNAS 101:8084–8089. DOI: https://doi.org/10.1073/pnas.0400841101, PMID: 15141086

Jewell JL, Russell RC, Guan KL. 2013. Amino acid signalling upstream of mTOR. Nature Reviews Molecular Cell Biology 14:133–139. DOI: https://doi.org/10.1038/nrm3522, PMID: 23361334

Jia K, Chen D, Riddle DL. 2004. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131:3897–3906. DOI: https://doi.org/10.1242/dev.01255, PMID: 15253933

Kalender A, Selvaraj A, Kim SY, Guliati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kosma SC, Thomas G. 2010. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metabolism 11:390–401. DOI: https://doi.org/10.1016/j.cmet.2010.03.014, PMID: 20444419

Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. 2008. Regulation of TORC1 by Rag GTPases in nutrient response. Nature Cell Biology 10:935–945. DOI: https://doi.org/10.1038/ncb1753, PMID: 18604198

Lapière LR, De Magalhaes Filho CD, McQuary PR, Chu CC, Visvikis O, Chang JT, Gelino S, Ong B, Davis AE, Irazoqui JE, Dillin A, Hansen M. 2013. The TFEB orthologue HLH-30 regulates autophagy and modulates longevity in Caenorhabditis elegans. Nature Communications 4:2267. DOI: https://doi.org/10.1038/ncomms3287, PMID: 23925298

LongoVD, AntebiA, BartkeA, BarzilaiN, Brown-BorgHM, CarusoC, Curiel TJ, de Cabo R, Franceschi C, Gems D, Ingram DK, Johnson TE, Kennedy BK, Kenyon C, Klein S, Kopchick JJ, Lepperdinger G, Mamede F, Mirmira RG, Mitchell JR, et al. 2015. Interventions to slow aging in humans: are we ready? Aging Cell 14:497–510. DOI: https://doi.org/10.1111/acel.12338, PMID: 25902704

Martin-Montalvo A, Mercenko EM, Mitchell SJ, Palacios HH, Mote PL, Scheibe-Byknudes M, Gomes AP, Ward TM, Minor RK, Blouin MJ, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, et al. 2013. Metformin improves healthspan and lifespan in mice. Nature Communications 4:2192. DOI: https://doi.org/10.1038/ncomms3192, PMID: 23900241

O’RourkeEJ, RuvkunG. 2013. MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability. Nature Cell Biology 15:668–676. DOI: https://doi.org/10.1038/ncc2741, PMID: 23604316

Onken B, Driscoll M. 2010. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 5:e8758. DOI: https://doi.org/10.1371/journal.pone.0008758, PMID: 20990912

Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 348:607–614. DOI: https://doi.org/10.1042/bj3480607, PMID: 10839993

Perera RM, ZoucuR. 2016. The lysosome as a regulatory hub. Annual Review of Cell and Developmental Biology 32:223–253. DOI: https://doi.org/10.1146/annurev-cellbio-111315-125125, PMID: 27501449

Rebida-Stubbbs S, Glover-Cutter K, Lamming DW, Mizunami M, Narasimhan SD, Neumann-Haeffelin E, Sabatini DM, Blackwell TK. 2012. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metabolism 15:713–724. DOI: https://doi.org/10.1016/j.cmet.2012.04.007, PMID: 22560223

Sancay P, Peterson TR, Shaul YD, Lindquist RA, Thorson CC, Bar-Peled L, Sabatini DM. 2008. The rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496–1501. DOI: https://doi.org/10.1126/science.1157535, PMID: 18497260

Sancay Y, Bar-Peled L, Zoucu R, Markhard AL, Nada S, Sabatini DM. 2010. Regulator-rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290–303. DOI: https://doi.org/10.1016/j.cell.2010.02.024, PMID: 20381137

Scarpello JH. 2003. Improving survival with metformin: the evidence base today. Diabetes & Metabolism 29:6536–6543. DOI: https://doi.org/10.1016/S1262-3636(03)72786-4, PMID: 14502099

Schmelze T, Hall MN. 2000. TOR, a central controller of cell growth. Cell 103:253–262. DOI: https://doi.org/10.1016/S0092-8674(00)01173-3, PMID: 11057998

Settembre C, Di Malta C, Poitol VA, Garcia Arenicbia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinszttein DC, Ballabio A. 2011. TFEB links autophagy to lysosomal biogenesis. Science 332:1429–1433. DOI: https://doi.org/10.1126/science.1204592, PMID: 21617040

Chen et al. eLife 2017;6:e31268. DOI: https://doi.org/10.7554/eLife.31268

16 of 17
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. 2004. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *PNAS* **101**:3329–3335. DOI: https://doi.org/10.1073/pnas.0308061100, PMID: 14985505

Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Müller F. 2003. Genetics: influence of TOR kinase on lifespan in *C. elegans*. *Nature* **426**:620. DOI: https://doi.org/10.1038/426620a, PMID: 14668850

Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Current Biology* **13**:2004–2008. DOI: https://doi.org/10.1016/j.cub.2003.10.031, PMID: 14614828

Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM, Mouri, Kacergis MC, Talkowski ME, Carr CE, Gygi SP, Zheng B, Soukas AA. 2016. An Ancient, Unified Mechanism for Metformin Growth Inhibition in *C. elegans* and Cancer. *Cell* **167**:1705–1718. DOI: https://doi.org/10.1016/j.cell.2016.11.055

Zhang YL, Guo H, Zhang CS, Lin SY, Yin Z, Peng Y, Luo H, Shi Y, Lian G, Zhang C, Li M, Ye Z, Ye J, Han J, Li P, Wu JW, Lin SC. 2013. AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation. *Cell Metabolism* **18**:546–555. DOI: https://doi.org/10.1016/j.cmet.2013.09.005, PMID: 24093678

Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, Wu YQ, Li TY, Liang Y, Lu Z, Lian G, Liu Q, Guo H, Yin Z, Ye Z, Han J, Wu JW, Yin H, Lin SY, Lin SC. 2014. The lysosomal v-ATPase-ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. *Cell Metabolism* **20**:526–540. DOI: https://doi.org/10.1016/j.cmet.2014.06.014, PMID: 25002183

Zhang CS, Li M, Ma T, Zong Y, Cui J, Feng JW, Wu YQ, Lin SY, Lin SC. 2016. Metformin activates AMPK through the lysosomal pathway. *Cell Metabolism* **24**:521–522. DOI: https://doi.org/10.1016/j.cmet.2016.09.003, PMID: 27732831

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. *Journal of Clinical Investigation* **108**:1167–1174. DOI: https://doi.org/10.1172/JCI13505, PMID: 11602624

Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nature Reviews Molecular Cell Biology* **12**:21–35. DOI: https://doi.org/10.1038/nrm3025, PMID: 21157483